A simple and sensitive stability indicating HPLC method is developed for the quantification
of rivaroxaban in bulk and tablet dosage form. Chromatographic separation was achieved …

A simple, precise and accurate HPLC method has been developed and validated for assay
of Rivaroxaban. An isocratic separation was achieved using a phenomenex C18 (250× 4.6 …

A simple, precise and accurate HPLC method has been developed and validated for assay
of Rivaroxaban. An isocratic separation was achieved using a phenomenex C18 (250× 4.6 …

Background: Solubility is an important physico-chemical factor affecting absorption of drug
and its therapeutic effectiveness. One of the major problems responsible for the low turnout …

Rivaroxaban (RIV) is an oral anticoagulant that is the first available orally active direct
inhibitor of factor Xa. This study focuses on a critical review of the mechanisms of action …

This work deals with the method development and validation of Rivaroxaban in
pharmaceutical dosage form on both the instruments HPLC and UPLC (technology transfer …

The present study is concerned with the development and validation of a bioanalytical
method for estimation of rivaroxaban in human plasma using high performance thin layer …

An efficient and high yielding process for the production of impurity free rivaroxaban (1), an
anti-coagulant agent using alternate synthon is reported. The key components of the …

This study aimed to evaluate the bioequivalence (BE) of 2 formulations of the 10‐mg
rivaroxaban tablet. The study was a randomized, open‐label, 4‐period, crossover study that …

Rivaroxaban (RIV) is an oral anticoagulant, used in the treatment of thromboembolic
ailments, myocardial infarction, stroke, angina pectoris and various blood clotting related …